Tivicay

Tivicay is the brand name for dolutegravir, an antiretroviral medication used to treat HIV-1 infection. It belongs to the class of integrase strand transfer inhibitors (INSTIs), which work by blocking the integration of HIV DNA into the host genome, thereby reducing viral replication. Dolutegravir is prescribed as part of combination antiretroviral therapy (cART) in adults and in certain pediatric populations.

Dolutegravir is approved for use in treatment-naive and certain treatment-experienced patients, typically as part of fixed‑dose or co-formulated regimens with other antiretrovirals. The choice of regimen depends on individual factors, including resistance testing results and coexisting conditions. It is commonly combined with other antiretrovirals to form an effective treatment plan.

The usual adult dose is 50 mg once daily. If used with rifampin-containing regimens (for tuberculosis), the dose is increased to 50 mg twice daily. Dolutegravir can be taken with or without food. It should be separated from polyvalent cations (such as calcium, iron, magnesium, aluminum, or zinc) by at least 2 hours before or 6 hours after dolutegravir dosing to minimize absorption issues.

Common adverse effects include trouble sleeping, headache, and fatigue. Some patients may experience weight changes or other metabolic effects. Dolutegravir has a relatively high barrier to resistance, though resistance can occur with certain viral mutations. Safety in pregnancy has been studied; periconception exposure has been associated with a small increased risk of neural tube defects in some studies, so patients planning pregnancy should discuss options with a clinician.

Tivicay is marketed by ViiV Healthcare and is available in multiple countries under appropriate regulatory approvals.